Drug Plans Decoded: Biosimilars Part 2
The Pharmacy Consulting Team at Telus Health looks at how Canada compares to Europe and the U.S. on biosimilars. Second in series.
Biosimilars news
Biosimilars Canada has compiled a list of news stories from Canada and abroad about biosimilars that may be of interest to readers. These links to third-party websites are provided for informational purposes only, and do represent an endorsement from our organization. Biosimilars Canada’s statements and news releases are available here.
Drug Plans Decoded: Biosimilars Part 1
The Pharmacy Consulting Team at Telus Health has published a good primer for private health insurers on biosimilars and the biosimilar landscape in Canada. First in series.
Alberta adds Humalog insulin lispro to biosimilar switching program
Effective August 1, adult patients covered by Alberta’s public drug plan who take Humalog insulin lispro will be required to switch to a biosimilar version by February 1, 2022. All new patient starts for insulin lispro will be covered for the biosimilar.
New Brunswick adds Lovenox enoxaparin to biosimilar switching program
New Brunswick has expanded its biosimilar switching program. Patients who take Lovenox enoxaparin will need to switch to an enoxaparin biosimilar by Feb 28, 2022. New patient starts for enoxaparin will also be covered for a biosimilar.
Alberta adds Lovenox enoxaparin to biosimilar switching program
Effective July 1, 2021, patients covered by Alberta’s public drug plan who take Lovenox enoxaparin are required to switch to an enoxaparin biosimilar by January 10, 2022. All new patient starts for enoxaparin will be covered for a biosimilar.
B.C.’s biosimilars policy a turning point for private plans
B.C.’s biosimilar switching policy has had a profound impact on private drug plans in the province, according to TELUS Health claims data for private drug plans.